TickerFiles

C4 Therapeutics, Inc. 10-Q filing

Filed 2026-05-12 · Report date 2026-03-31 · 2026

View Original SEC Filing

Filing metadata

Accession number
0001628280-26-033865
Form type
10-Q
CIK
0001662579
Primary document
https://www.sec.gov/Archives/edgar/data/1662579/000162828026033865/cccc-20260331.htm

Extracted primary information

This filing includes deterministic financial metrics extracted from public filing data for C4 Therapeutics, Inc..

Reported financial metrics

MetricCurrentPriorChange
Revenue$6.2M--
Operating Income$-27.8M--
Net Income$-25.1M--
Eps Basic-0.2--
Eps Diluted-0.2--
Cash And Equivalents$61.3M--
Total Assets$328.9M--
Total Liabilities$94.6M--
Shareholders Equity$234.2M--
Operating Cash Flow$-29.9M--
Capital Expenditures$64,000--